Efficacy of metoprolol CR/XL on diabetic postoperative mortality and cardiovascular morbidity: a randomised, double blind, placebo-controlled, multicentre trial

Conditions

Diabetes mellitus and major surgery Nutritional, Metabolic, Endocrine Diabetes mellitus

Juul AB, Wetterslev J, Gluud C, Kofoed-Enevoldsen A, Jensen G, Callesen T, Nørgaard P, Fruergaard K, Bestle M, Vedelsdal R, Miran A, Jacobsen J, Roed J, Mortensen MB, Jørgensen L, Jørgensen J, Rovsing ML, Petersen PL, Pott F, Haas M, Albret R, Nielsen LL, Johansson G, Stjernholm P, Mølgaard Y, Foss NB, Elkjaer J, Dehlie B, Boysen K, Zaric D, Munksgaard A, Madsen JB, Øberg B, Khanykin B, Blemmer T, Yndgaard S, Perko G, Wang LP, Winkel P, Hilden J, Jensen P, Salas N, DIPOM Trial Group.

2006-06-01184 citations

10.1136/bmj.332.7556.1482

Interventions

Diabetic patients undergoing major noncardiac surgery are randomised to 7 days of perioperative beta blocking (Metoprolol CR/XL [SeloZok®] 100 mg daily) versus placebo treatment.

Eligibility

Inclusion criteria

Inclusion criteria: Patients 40 years of age with diabetes undergoing noncardiac major (lasting more than 1 hour) surgery

Exclusion criteria

Exclusion criteria: Not provided at time of registration

Design outcomes

Primary

Measure	Time frame
Not provided at time of registration	—

Secondary

Measure	Time frame
Not provided at time of registration	—

Countries

Denmark

Outcome results

None listed